Frequently Asked Questions about Elzonris (tagraxofusp-erzs)

Understand the administration, side effects and answers to frequently asked questions about Elzonris

Generic Name: tagraxofusp-erzs

Trade Name: Elzonris®

For which conditions is Elzonris approved for? Elzonris is indicated for the treatment of adults and children 2 years or older with blastic plasmacytoid dendritic cell neoplasm (BPDCN). The labeling contains a boxed warning to alert healthcare professionals and patients about potential severe and/or life-threatening side effects of capillary leak syndrome (CLS).

What is the mechanism of action? Elzonris works by causing cell death in CD123-expressing cells.

How is Elzonris typically given (administered)? Elzonris is administered intravenously on days 1 through 5, every 21 days.

How are patients typically monitored? During treatment with Elzonris, at a minimum your healthcare provider will do blood tests to check your blood counts and liver function tests as well as monitor you for signs or symptoms of CLS. Elzonris may harm an unborn baby. Do not breastfeed during treatment with Elzonris and for at least 1 week after the last dose of Elzonris.

What are the common (occur in 30% or more of patients) side effects of treatment with Elzonris?

  • Capillary leak syndrome
  • Nausea
  • Fatigue
  • Peripheral edema
  • Fever
  • Weight increase

This is not a complete list of side effects. Some patients may experience other side effects that are not listed here. Patients may wish to discuss with their physician the other less common side effects of this drug, some of which may be serious.

Some side effects may require medical attention. Other side effects do not require medical attention and may go away during treatment. Patients should check with their physician about any side effects that continue or are bothersome.

What can patients do to help alleviate or prevent discomfort and side effects?

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Elzonris and certain other medicines may affect each other. Know the medicines you take. Keep a list of your medicines and show it to your doctor and pharmacist when you get a new medicine.

Are there any special precautions patients should be aware of before starting treatment?

Tell your doctor about all of your medical conditions and tell your doctor if you or your partner are pregnant or are planning on becoming pregnant and if you are breastfeeding. Elzonris may cause serious side effects.

When should patients notify their physician? Tell your doctor if you experience any side effects that bother you or don’t go away. You should also contact your healthcare provider if you experience hypersensitivity reactions including rash, flushing, wheezing or swelling of the face.

ELZONRIS may cause severe or life-threatening side effects from CLS and it is important that you weigh yourself every day and call your healthcare provider right away if you experience any of the following symptoms:

· New or worsening swelling

· Weight gain

· Shortness of breath

· Hypotension after infusion

What is a package insert?

A package insert is required by the FDA and contains a summary of the essential scientific information needed for the safe and effective use of the drug for healthcare providers and consumers. A package insert typically includes information regarding specific indications, administration schedules, dosing, side effects, contraindications, results from some clinical trials, chemical structure, pharmacokinetics and metabolism of the specific drug. By carefully reviewing the package insert, you will get the most complete and current information about how to safely use this drug. If you do not have the package insert for the drug you are using, your pharmacist or physician may be able to provide you with a copy.

Important Limitations of Use

The information provided above on the drug you have selected is provided for your information only and is not a substitute for consultation with an appropriate medical doctor. We are providing this information solely as a courtesy and, as such, it is in no way a recommendation as to the safety, efficacy or appropriateness of any particular drug, regimen, dosing schedule for any particular cancer, condition or patient nor is it in any way to be considered medical advice. Patients should discuss the appropriateness of a particular drug or chemotherapy regimen with their physician.

As with any printed reference, the use of particular drugs, regimens and drug dosages may become out-of-date over time, since new information may have been published and become generally accepted after the latest update to this printed information. Please keep in mind that health care professionals are fully responsible for practicing within current standards, avoiding use of outdated regimens, employing good clinical judgment kin selecting drugs and/or regimens, in calculating doses for individual patients, and verifying all dosage calculations.

DISCLAIMER OF WARRANTIES

CANCERCONNECT SPECIFICALLY DISCLAIMS AND EXCLUDES ALL EXPRESSED OR IMPLIED WARRANTIES, INCLUDING ANY IMPLIED WARRANTIES AS TO QUALITY, ACCURACY (INCLUDING TYPOGRAPHICAL ERRORS), MERCHANTABILITY, OR FITNESS FOR ANY PARTICULAR PURPOSE OF THE INFORMATION CONTAINED HEREIN. CANCERCONNECT DISCLAIMS ALL LIABILITY OR DAMAGES ARISING FROM ANY USE OF THE INFORMATION.

The prescribing physician is solely responsible for making all decisions relating to appropriate patient care including, but not limited to, drugs, regimens, dose, schedule, and any supportive care.

Comments